<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>1214</number>
    <updateDate>2025-11-19T03:11:22Z</updateDate>
    <updateDateIncludingText>2025-11-19T03:11:22Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <originChamberCode>S</originChamberCode>
    <type>S</type>
    <introducedDate>2023-04-19</introducedDate>
    <congress>118</congress>
    <legislationUrl>https://www.congress.gov/bill/118th-congress/senate-bill/1214</legislationUrl>
    <committees>
      <item>
        <systemCode>sshr00</systemCode>
        <name>Health, Education, Labor, and Pensions Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Reported By</name>
            <date>2023-06-22T17:37:36Z</date>
          </item>
          <item>
            <name>Markup By</name>
            <date>2023-05-11T14:00:00Z</date>
          </item>
          <item>
            <name>Referred To</name>
            <date>2023-04-19T20:24:50Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Give Kids a Chance Act of 2024</title>
        <congress>118</congress>
        <number>3433</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2024-09-24</actionDate>
          <text>Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>RARE Act</title>
        <congress>118</congress>
        <number>7383</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2024-02-16</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2023-06-22</actionDate>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 109.</text>
        <type>Calendars</type>
      </item>
      <item>
        <actionDate>2023-06-22</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on Health, Education, Labor, and Pensions. Reported by Senator Sanders without amendment. Without written report.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2023-06-22</actionDate>
        <text>Committee on Health, Education, Labor, and Pensions. Reported by Senator Sanders without amendment. Without written report.</text>
        <type>Committee</type>
        <actionCode>14000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2023-05-11</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on Health, Education, Labor, and Pensions. Ordered to be reported without amendment favorably.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2023-04-19</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2023-04-19</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>B001230</bioguideId>
        <fullName>Sen. Baldwin, Tammy [D-WI]</fullName>
        <firstName>Tammy</firstName>
        <lastName>Baldwin</lastName>
        <party>D</party>
        <state>WI</state>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>B001310</bioguideId>
        <fullName>Sen. Braun, Mike [R-IN]</fullName>
        <firstName>Mike</firstName>
        <lastName>Braun</lastName>
        <party>R</party>
        <state>IN</state>
        <sponsorshipDate>2023-04-26</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
          <updateDate>2023-06-08T19:45:24Z</updateDate>
        </item>
        <item>
          <name>Drug therapy</name>
          <updateDate>2023-06-08T19:45:24Z</updateDate>
        </item>
        <item>
          <name>Licensing and registrations</name>
          <updateDate>2023-06-08T19:45:24Z</updateDate>
        </item>
        <item>
          <name>Prescription drugs</name>
          <updateDate>2023-06-08T19:45:24Z</updateDate>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
        <updateDate>2023-04-27T16:45:54Z</updateDate>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2023-04-19</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2023-11-29T20:23:41Z</updateDate>
        <cdata>
          <text>&lt;p&gt;&lt;b&gt;Retaining Access and Restoring Exclusivity Act or the RARE Act&lt;/b&gt;&lt;/p&gt; &lt;p&gt;This bill specifies that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drug exclusivity period) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition.&lt;/p&gt; &lt;p&gt;Current law grants a seven-year period of market exclusivity for an approved orphan drug, during which the Food and Drug Administration (FDA) may not approve an application from another manufacturer for the same drug for the same disease or condition. The FDA's regulations provide that this exclusivity is specific to the same approved use or indication of the drug, rather than all uses or indications, for the disease or condition. However, in &lt;i&gt;Catalyst Pharmaceuticals, Inc. v. Becerra, &lt;/i&gt;a court held that exclusivity did extend to all uses or indications for the disease or condition.&lt;/p&gt; &lt;p&gt;The bill provides statutory authority for the FDA's regulations. &lt;/p&gt;</text>
        </cdata>
      </summary>
      <summary>
        <versionCode>25</versionCode>
        <actionDate>2023-06-22</actionDate>
        <actionDesc>Reported to Senate</actionDesc>
        <updateDate>2023-11-29T21:17:20Z</updateDate>
        <cdata>
          <text>&lt;p&gt;&lt;b&gt;Retaining Access and Restoring Exclusivity Act or the RARE Act&lt;/b&gt;&lt;/p&gt; &lt;p&gt;This bill specifies that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drug exclusivity period) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition.&lt;/p&gt; &lt;p&gt;Current law grants a seven-year period of market exclusivity for an approved orphan drug, during which the Food and Drug Administration (FDA) may not approve an application from another manufacturer for the same drug for the same disease or condition. The FDA's regulations provide that this exclusivity is specific to the same approved use or indication of the drug, rather than all uses or indications, for the disease or condition. However, in &lt;i&gt;Catalyst Pharmaceuticals, Inc. v. Becerra, &lt;/i&gt;a court held that exclusivity did extend to all uses or indications for the disease or condition.&lt;/p&gt; &lt;p&gt;The bill provides statutory authority for the FDA's regulations. &lt;/p&gt;</text>
        </cdata>
      </summary>
    </summaries>
    <title>RARE Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <titleTypeCode>45</titleTypeCode>
        <title>RARE Act</title>
        <updateDate>2024-07-24T15:21:49Z</updateDate>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <titleTypeCode>101</titleTypeCode>
        <title>RARE Act</title>
        <updateDate>2024-05-24T13:40:49Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <titleTypeCode>101</titleTypeCode>
        <title>Retaining Access and Restoring Exclusivity Act</title>
        <updateDate>2024-05-24T13:40:49Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate</titleType>
        <titleTypeCode>103</titleTypeCode>
        <title>RARE Act</title>
        <updateDate>2024-05-24T13:39:13Z</updateDate>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate</titleType>
        <titleTypeCode>103</titleTypeCode>
        <title>Retaining Access and Restoring Exclusivity Act</title>
        <updateDate>2024-05-24T13:39:13Z</updateDate>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <titleTypeCode>6</titleTypeCode>
        <title>A bill to set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions.</title>
        <updateDate>2023-04-26T01:58:43Z</updateDate>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Reported to Senate</type>
        <date>2023-06-22T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-118s1214rs/xml/BILLS-118s1214rs.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Introduced in Senate</type>
        <date>2023-04-19T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-118s1214is/xml/BILLS-118s1214is.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2023-06-22</actionDate>
      <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 109.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
